Molecular mechanisms involved in the protective role of olive oil in the development of atherosclerotic processes

Molecular mechanisms involved in the protective role of olive oil in the development of atherosclerotic processes: a parallel randomised controlled double-blind clinical trial with three arms of dietary intervention

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN53283428

Enrollment

Registered

2009-07-28

Start date

2007-10-20

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular risk Circulatory System Cardiovascular risk

Interventions

Volunteers were grouped randomly into three groups (n = 30 each one) to receive during 3 months the following treatments: 1. Traditional Mediterranean diet with virgin olive oil (TMD+VOO) 2. Traditio

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Healthy volunteers aged 20 - 50 years old, either sex

Exclusion criteria

Exclusion criteria: 1. Intake of antioxidant supplements 2. Intake of acetosalicylic acid 3. Intake of any other drug with established antioxidative properties 4. Athletes with high physical activity (greater than 3000 kcal per week in leisure-time physical activity) 5. Obesity (body mass index [BMI] greater than 30 kg/m^2) 6. Hypercholestrolaemia greater than 8.0 mmol per litre or dyslipidaemia therapy indication 7. Diabetes 8. Hypertension (systolic blood pressure [SBP] greater than 140 mmHg, diastolic blood pressure [DBP] greater than 90 mmHg) 9. Multiple allergies 10. Coeliac or other intestinal diseases 11. Any condition that limits the mobility of the subject making study visits impossible 12. Life-threatening illnesses such as cancer or a severe disease with a less than 3-year expectancy 13. Other diseases or conditions that could worsen adherence to the measurements or treatments 14. Vegetarians and people following special diets 15. Alcoholism or other drug addiction

Design outcomes

Primary

Measure	Time frame
Gene expression changes related to cardiovascular risk, measured at baseline and after 3 months of intervention. Blood samples were collected from 8.00 to 10.00 a.m. at fasting state. Spot morning urine samples were collected.	—

Secondary

Measure	Time frame
Oxidative stress and Inflammation, measured at baseline and after 3 months of intervention. Blood samples were collected from 8.00 to 10.00 a.m. at fasting state. Spot morning urine samples were collected.	—

Countries

Spain

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026